Cibus, Inc. Announces Pricing of $20.0 Million Public Offering of Class A Common Stock
Rhea-AI Summary
Cibus (Nasdaq: CBUS) priced an underwritten public offering of 13,333,333 shares of Class A common stock at $1.50 per share, generating gross proceeds of approximately $20.0 million (or $23.0 million if the underwriter fully exercises a 30-day option).
Board members agreed to purchase 1,000,000 shares. The offering is expected to close on January 30, 2026, with net proceeds intended for working capital and to fund development of weed management traits in rice.
Positive
- Gross proceeds of approximately $20.0 million
- Board purchase of 1,000,000 shares signals insider participation
- Proceeds earmarked to fund rice weed-management trait development
Negative
- Issuance of 13,333,333 new shares will dilute existing shareholders
- Net proceeds reduced by underwriting discounts, commissions, and expenses
- Closing subject to customary conditions; offering may not complete as expected
News Market Reaction – CBUS
On the day this news was published, CBUS gained 9.09%, reflecting a notable positive market reaction. Argus tracked a peak move of +30.3% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $110M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CBUS was down 2.22% while peers were mixed: ACET -1.05%, CVM -4.69%, IGMS -2.31%, VANI +7.97%, RPTX +0.38%. No peers appeared in momentum scans, pointing to a stock-specific reaction to the financing.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | Proposed equity offering | Negative | -2.2% | Announcement of proposed underwritten stock offering for working capital and rice traits. |
| Jun 09 | Offering closing | Negative | -0.6% | Closing of <b>$27.5M</b> common stock offering at <b>$1.75</b> per share. |
| Jun 05 | Offering pricing | Negative | -34.3% | Pricing of <b>$27.5M</b> public offering at <b>$1.75</b> per share. |
| Jun 04 | Proposed offering | Negative | -34.3% | Proposed public stock offering with chairman interest to purchase shares. |
| Jan 21 | Registered direct deal | Negative | -5.7% | <b>$22.6M</b> registered direct deal with shares and warrants at <b>$2.50</b> per share. |
Equity offerings have consistently led to negative single-day moves, with all 5 prior offering-related events showing declines.
Over the past year, Cibus has repeatedly relied on equity financings, including a $22.6M registered direct offering at $2.50 per share in Jan 2025 and a $27.5M public offering at $1.75 per share in Jun 2025. These deals, plus the recent proposed offering on Jan 28, 2026, all resulted in negative price reactions, underscoring persistent dilution pressure that today’s pricing announcement continues.
Historical Comparison
In the past year, CBUS reported 5 offering-related events with an average one-day move of 15.42% in magnitude, typically negative, indicating that equity raises have been significant trading catalysts.
Cibus has repeatedly raised equity capital: a $22.6M registered direct in Jan 2025, a $27.5M public offering in Jun 2025, and subsequent proposed and priced offerings, largely to fund rice weed-management traits and working capital.
Market Pulse Summary
The stock moved +9.1% in the session following this news. A strong positive reaction aligns with the importance of balance-sheet extension for Cibus, which historically relied on equity raises such as the $22.6M and $27.5M offerings in 2025. However, past offering-related headlines usually saw negative moves, so any sharp upside could reflect short-term positioning or perceived de-risking rather than a shift in dilution concerns, and might prove sensitive to follow-on financing needs.
Key Terms
underwritten public offering financial
over-allotments financial
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the pricing of an underwritten public offering of 13,333,333 shares of its Class A Common Stock, par value
The Company has also granted the underwriter a 30-day option to purchase up to an additional 1,999,999 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the Offering are to be sold by the Company.
The gross proceeds of the Offering will be approximately
BTIG, LLC is acting as the sole underwriter for the Offering.
This Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273062), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 30, 2023, as amended on October 25, 2023, and declared effective by the SEC on October 27, 2023. A prospectus supplement describing the terms of the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained from BTIG, LLC, at 65 East 55th Street, New York, New York 10022 or by telephone at (212) 593-7555, or by email at ProspectusDelivery@btig.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cibus
Cibus is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus’ proprietary high-throughput gene-editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated closing of the Offering and the expected use of the proceeds from the Offering. Completion of the Offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements made by Cibus’ management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
CIBUS CONTACTS:
INVESTOR RELATIONS
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
media@cibus.com
Colin Sanford
colin@bioscribe.com
203-918-4347
FAQ
What are the key terms of Cibus (CBUS) public offering on January 29, 2026?
How much will Cibus (CBUS) raise and what could increase that amount?
Why are Cibus (CBUS) using the net proceeds from the January 2026 offering?
Did company insiders participate in the Cibus (CBUS) offering and what does that mean?
When will the Cibus (CBUS) offering close and who is the underwriter?
